AMGN – Amgen Inc.
Amgen Inc.AMGN
$296.70Name : Amgen Inc.
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $159,731,974,144.00
EPSttm : 12.24
Amgen Inc.
$296.70
0.13%$0.372Float Short %
2.14
Margin Of Safety %
12
Put/Call OI Ratio
0.65
EPS Next Q Diff
-0.94
EPS Last/This Y
13.42
EPS This/Next Y
0.52
Price
297.06
Target Price
311.12
Analyst Recom
2.39
Performance Q
4.23
Relative Volume
1.48
Beta
0.46
Ticker: AMGN
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-10-06 | AMGN | 294.13 | 0.84 | 0.65 | 145964 |
| 2025-10-07 | AMGN | 295.54 | 0.84 | 0.48 | 147603 |
| 2025-10-08 | AMGN | 294.68 | 0.83 | 0.35 | 148727 |
| 2025-10-09 | AMGN | 295.42 | 0.82 | 0.64 | 150210 |
| 2025-10-10 | AMGN | 290.29 | 0.80 | 0.46 | 152410 |
| 2025-10-13 | AMGN | 292.41 | 0.81 | 0.51 | 140017 |
| 2025-10-14 | AMGN | 293.9 | 0.81 | 0.38 | 140655 |
| 2025-10-15 | AMGN | 297.32 | 0.80 | 0.14 | 143081 |
| 2025-10-16 | AMGN | 295.82 | 0.77 | 0.30 | 147832 |
| 2025-10-17 | AMGN | 298.81 | 0.78 | 0.35 | 148648 |
| 2025-10-20 | AMGN | 303.33 | 0.72 | 0.08 | 115091 |
| 2025-10-21 | AMGN | 301.01 | 0.66 | 0.41 | 123275 |
| 2025-10-22 | AMGN | 295.9 | 0.65 | 0.58 | 125597 |
| 2025-10-23 | AMGN | 292.99 | 0.66 | 0.33 | 127401 |
| 2025-10-24 | AMGN | 291.96 | 0.65 | 0.39 | 128070 |
| 2025-10-27 | AMGN | 291.15 | 0.71 | 0.46 | 117437 |
| 2025-10-28 | AMGN | 292.12 | 0.70 | 0.20 | 120752 |
| 2025-10-29 | AMGN | 291.76 | 0.68 | 0.23 | 123439 |
| 2025-10-30 | AMGN | 291.93 | 0.68 | 0.76 | 123959 |
| 2025-10-31 | AMGN | 298.5 | 0.67 | 0.15 | 124750 |
| 2025-11-03 | AMGN | 296.24 | 0.66 | 0.31 | 121052 |
| 2025-11-04 | AMGN | 309.04 | 0.65 | 0.75 | 124439 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-10-06 | AMGN | 294.09 | -9.9 | 5083.7 | 21.08 |
| 2025-10-07 | AMGN | 295.45 | -9.9 | 5271.0 | 21.08 |
| 2025-10-08 | AMGN | 294.60 | -9.9 | 5178.9 | 21.08 |
| 2025-10-09 | AMGN | 295.35 | -9.9 | 5246.6 | 21.08 |
| 2025-10-10 | AMGN | 290.14 | -9.9 | 5002.9 | 21.08 |
| 2025-10-13 | AMGN | 292.41 | -9.9 | 5310.6 | 21.09 |
| 2025-10-14 | AMGN | 293.95 | -9.8 | 5280.0 | 21.08 |
| 2025-10-15 | AMGN | 297.37 | -9.8 | 5360.0 | 21.08 |
| 2025-10-16 | AMGN | 295.76 | -9.8 | 5154.1 | 21.08 |
| 2025-10-17 | AMGN | 298.82 | -9.8 | 5338.7 | 21.08 |
| 2025-10-20 | AMGN | 303.33 | -9.8 | 5398.3 | 21.08 |
| 2025-10-21 | AMGN | 301.10 | -9.8 | 5128.6 | 21.08 |
| 2025-10-22 | AMGN | 295.98 | -9.7 | 5011.2 | 21.08 |
| 2025-10-23 | AMGN | 292.98 | -9.7 | 5095.7 | 21.08 |
| 2025-10-24 | AMGN | 291.80 | -10.1 | 5172.6 | 21.05 |
| 2025-10-27 | AMGN | 291.06 | -10.1 | 5188.4 | 21.05 |
| 2025-10-28 | AMGN | 292.09 | -10.1 | 5255.1 | 21.04 |
| 2025-10-29 | AMGN | 291.78 | -10.1 | 5204.3 | 21.04 |
| 2025-10-30 | AMGN | 292.00 | -10.1 | 5226.4 | 21.04 |
| 2025-10-31 | AMGN | 298.45 | -10.1 | 5480.2 | 21.04 |
| 2025-11-03 | AMGN | 296.23 | -10.1 | 5128.7 | 21.04 |
| 2025-11-04 | AMGN | 297.06 | -10.1 | 5247.7 | 21.04 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-10-06 | AMGN | -0.35 | 0.47 | 2.46 |
| 2025-10-07 | AMGN | -0.35 | 0.47 | 2.46 |
| 2025-10-08 | AMGN | -0.35 | 0.47 | 2.46 |
| 2025-10-09 | AMGN | -0.35 | 0.47 | 2.46 |
| 2025-10-10 | AMGN | -0.35 | 0.47 | 2.40 |
| 2025-10-13 | AMGN | -0.35 | 0.29 | 2.40 |
| 2025-10-14 | AMGN | -0.35 | 0.29 | 2.40 |
| 2025-10-15 | AMGN | -0.35 | 0.29 | 2.40 |
| 2025-10-16 | AMGN | -0.35 | 0.29 | 2.40 |
| 2025-10-17 | AMGN | -0.35 | 0.29 | 2.40 |
| 2025-10-20 | AMGN | -0.35 | 0.09 | 2.40 |
| 2025-10-21 | AMGN | -0.35 | 0.09 | 2.40 |
| 2025-10-22 | AMGN | -0.35 | 0.09 | 2.40 |
| 2025-10-23 | AMGN | -0.35 | 0.09 | 2.40 |
| 2025-10-24 | AMGN | -0.35 | 0.09 | 2.40 |
| 2025-10-27 | AMGN | -0.35 | -0.10 | 2.14 |
| 2025-10-28 | AMGN | -0.35 | -0.10 | 2.14 |
| 2025-10-29 | AMGN | -0.35 | -0.10 | 2.14 |
| 2025-10-30 | AMGN | -0.35 | -0.10 | 2.14 |
| 2025-10-31 | AMGN | -0.35 | -0.10 | 2.14 |
| 2025-11-03 | AMGN | -0.37 | -0.18 | 2.14 |
| 2025-11-04 | AMGN | -0.37 | -0.18 | 2.14 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
6.02
Avg. EPS Est. Current Quarter
5.02
Avg. EPS Est. Next Quarter
5.08
Insider Transactions
-0.37
Institutional Transactions
-0.18
Beta
0.46
Average Sales Estimate Current Quarter
8982
Average Sales Estimate Next Quarter
9356
Fair Value
332.13
Quality Score
85
Growth Score
88
Sentiment Score
70
Actual DrawDown %
14.3
Max Drawdown 5-Year %
-24.9
Target Price
311.12
P/E
24.27
Forward P/E
13.76
PEG
5.82
P/S
4.59
P/B
21.5
P/Free Cash Flow
15.06
EPS
12.22
Average EPS Est. Cur. Y
21.04
EPS Next Y. (Est.)
21.57
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
19.04
Relative Volume
1.48
Return on Equity vs Sector %
63.2
Return on Equity vs Industry %
52.4
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.03
EBIT Estimation
5247.7
Amgen Inc.Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 28000
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
stock quote shares AMGN – Amgen Inc. Stock Price stock today
news today AMGN – Amgen Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch AMGN – Amgen Inc. yahoo finance google finance
stock history AMGN – Amgen Inc. invest stock market
stock prices AMGN premarket after hours
ticker AMGN fair value insiders trading